Management of pediatric acute leukemias relapse after hematopoietic cell transplantation
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e285Keywords:
Leukemia, Neoplasm, Residual, Chimerism, MaintenanceAbstract
Prevention is the best way to avoid relapse after hematopoietic cell transplantation (HCT). Immunomodulation can enhance graft-versus-leukemia effect and, if graft-versus-host disease (GVHD) is absent, prophylactic donor lymphocyte infusion (DLI) may be indicated for high-risk patients. Maintenance strategies with blinatumomab, inotuzumab, tyrosine kinase inhibitors, hypomethylating agents or venetoclax can be effective in reducing relapse rates. However, maintenance therapy response depends on individual toxicity and physician’s experience in handle with dose adjustments, undesirable drug interactions and complications. Preemptive approach guided by minimal residual disease (MRD) or mixed chimerism is fundamental to prevent hematologic relapse. Target agent or immunotherapy followed by DLI can be used, and if no response, low-dose chemotherapy can be added to reach disease control. After relapse, antigen-directed therapies with blinatumumab for CD19 ALL and inotuzumab for CD22 ALL are good options to induce MRD negativity and bridge to second HCT. Emerging therapies like daratumumab, immune checkpoint or menin inhibitors are promising but require validation. CAR-T cell therapy can provide a better chance of long-term survival if low leukemia burden and absence of GVHD. It is also effective in extramedullary disease, mainly in central nervous system relapse. Patients with B-cell aplasia loss after CAR T-cell therapy are second transplant candidates, as well as those with acute myeloid leukemia who respond to salvage therapy. Second HCT outcomes are better if relapse occurred ≥ 12 months after the first HCT. Strategies for expanding access to immunotherapy and target agents are crucial to improve long-term survival in these children.
References
1. Pelegrina PRD, Tavares RCB, Rodrigues AM, Loth G, Nichele S, Kuwahara C, Benini FML, Peixoto CMA, Bach J, Trennepohl J, de Gouvea LMM, Muratori R, Koliski A, Gomes RT, Quiroga M, Lermontov SP, da Silva VG, de Azambuja AP, Feitosa MK, Lima ACM, Bonfim C. Clinical outcomes and relapse patterns in pediatric acute leukemia patients undergoing hematopoietic cell transplantation: a multicenter Brazilian experience. Front Pediatr. 2025;13:1573334. https://doi.org/10.3389/fped.2025.1573334 DOI: https://doi.org/10.3389/fped.2025.1573334
2. Tavares RCB, Bonfim CS, Seber A, Pereira Lermontov S, Coulturato V, Zecchin VG, Ribeiro L, Fernandes JF, Daudt LE, Grecco CS, Darrigo-Jr. LG, Villela N, Nichele S, Gouveia R, Bouzas LF, Hamerschlak N, Vigorito AC, da Silva PM, da Silva PO, da Silva CC, de Souza Fernandez C, Flowers ME, Arcuri LJ. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. Pediatr Transplant. 2020;24(7):e13789. https://doi.org/10.1111/petr.13789 DOI: https://doi.org/10.1111/petr.13789
3. Marjańska A, Pogorzała M, Dziedzic M, Czyżewski K, Richert-Przygońska M, Dębski R, Bogiel T, Styczynski J. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children. Front Immunol. 2024;15:1427637. https://doi.org/10.3389/fimmu.2024.1427637 DOI: https://doi.org/10.3389/fimmu.2024.1427637
4. Breviglieri CNM, Gouveia RV, Ginani VC, Santos CN, de Oliveira MRS, Batalha ABW, de Alencar GS, Goto EH, Marques JF, Pupim MPV, Seber A. Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective. Front Oncol. 2025;15:1540158. https://doi.org/10.3389/fonc.2025.1540158 DOI: https://doi.org/10.3389/fonc.2025.1540158
5. Ueda M, de Lima M, Caimi P, Tomlinson B, Little J, Creger R, Lazarus H, Cooper B. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2016;51(9):1253–5. https://doi.org/10.1038/bmt.2016.104 DOI: https://doi.org/10.1038/bmt.2016.104
6. Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022;139(12):1908–19. https://doi.org/10.1182/blood.2021013290 DOI: https://doi.org/10.1182/blood.2021013290
7. Huang J, Shi B, Yu S, Xue M, Wang L, Jiang J, Hu J, Zhu J, Chen S, Shen L, Cao W, Cao Y, Hu X. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation. Blood Cancer J. 2024;14(1):109. https://doi.org/10.1038/s41408-024-01092-w DOI: https://doi.org/10.1038/s41408-024-01092-w
8. Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, Ciarrone L, Kopp S, Convents RD, Majhail N, Caimi PF, Otegbeye F, Cooper BW, Gallogly M, Malek E, Tomlinson B, Gerds AT, Hamilton B, Giralt S, Perales MA, de Lima M. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024;8(6):1384–91. https://doi.org/10.1182/bloodadvances.2023011514 DOI: https://doi.org/10.1182/bloodadvances.2023011514
9. Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392–9. https://doi.org/10.3324/haematol.2014.116954 DOI: https://doi.org/10.3324/haematol.2014.116954
10. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL. Blood. 2020;136(15):1786–9. https://doi.org/10.1182/blood.2019004685 DOI: https://doi.org/10.1182/blood.2019004685
11. Oran B, Champlin R, Thall P, McCarty J, Zhang W, Marin D, Mehta RS, Alousi AM, Alatrash G, Popat UR, Kantarjian H, Bashir Q, Shpall EJ, Konopleva M. Phase II trial of venetoclax (Ven) in combination with azacitidine (AZA) As maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation (SCT). Blood. 2022;140(Suppl. 1):10561–2. https://doi.org/10.1182/blood-2022-159312 DOI: https://doi.org/10.1182/blood-2022-159312
12. Hassan MA, Moukalled N, El Cheikh J, Bazarbachi A, Abou Dalle I. Azacitidine in combination with venetoclax maintenance post-allogeneic hematopoietic stem cell transplantation in T cell acute lymphoblastic leukemia. Clin Hematol Int. 2023;5(1):52–5. https://doi.org/10.1007/s44228-022-00019-1 DOI: https://doi.org/10.1007/s44228-022-00019-1
13. Kungwankiattichai S, Ponvilawan B, Roy C, Tunsing P, Kuchenbauer F, Owattanapanich W. Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Front Med. 2022; 9: 801632. https://doi.org/10.3389/fmed.2022.801632 DOI: https://doi.org/10.3389/fmed.2022.801632
14. Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, Jiang M, Bai H, Lang T, Wang J, Liu L, Yang T, Huang X, Liu F, Lou S, Liu Y, Zhang C, Liu H, Gao L, Liu J, Zhu L, Wen Q, Chen T, Wang P, Rao J, Mao M, Wang C, Duan X, Luo L, Peng X, Cassady K, Zhong JF, Zhang X. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020;38(36):4249–59. https://doi.org/10.1200/jco.19.03277 DOI: https://doi.org/10.1200/JCO.19.03277
15. Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023;58(8):849–54. https://doi.org/10.1038/s41409-023-01987-5 DOI: https://doi.org/10.1038/s41409-023-01987-5
16. Ohga S, Yamauchi T, Yoshimoto G, Kato K, Akashi K. Overcoming high-risk MDS/AML post-allogeneic HSCT: venetoclax and azacitidine as maintenance therapy. Blood. 2024;144(Suppl. 1):5973. https://doi.org/10.1182/blood-2024-202428 DOI: https://doi.org/10.1182/blood-2024-202428
17. Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Contreras ME, Fell G, Letai A, Ritz J, Lindsley RC, Soiffer RJ, Antin JH. Prophylactic maintenance with venetoclax/azacitidine after reducedintensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024; 8(4): 978–90. https://doi.org/10.1182/bloodadvances.2023012120 DOI: https://doi.org/10.1182/bloodadvances.2023012120
18. Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002. https://doi.org/10.1200/jco.19.03345 DOI: https://doi.org/10.1200/JCO.19.03345
19. Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Wang Z, Jiang L, Yu C, Zhou X, Lin R, Chen Y, Tu S, Huang X, Liu Q. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an openlabel, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201–12. https://doi.org/10.1016/s1470-2045(20)30455-1 DOI: https://doi.org/10.1016/S1470-2045(20)30455-1
20. Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/ MORPHO Study Investigators. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766–75. https://doi.org/10.1200/jco.23.02474 DOI: https://doi.org/10.1200/JCO.23.02474
21. Miura S, Ueda K, Minakawa K, Nollet KE, Ikeda K. Prospects and potential for chimerism analysis after allogeneic hematopoietic stem cell transplantation. Cells. 2024;13(11):993. https://doi.org/10.3390/cells13110993 DOI: https://doi.org/10.3390/cells13110993
22. Blouin AG, Askar M. Chimerism analysis for clinicians: a review of the literature and worldwide practices. Bone Marrow Transplant. 2022;57(3):347–59. https://doi.org/10.1038/s41409-022-01579-9 DOI: https://doi.org/10.1038/s41409-022-01579-9
23. Haugaard AK, Madsen HO, Marquart HV, Rosthøj S, Masmas TN, Heilmann C, Müller KG, Ifversen M. Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia. Pediatr Transplant. 2019; 23(7):13549. https://doi.org/10.1111/petr.13549 DOI: https://doi.org/10.1111/petr.13549
24. Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, Poetschger U, Stachel D, Schrappe M, Alten J, Schrauder A, Schulz A, Lang P, Müller I, Albert MH, Willasch AM, Klingebiel TE, Peters C. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33(11):1275–84. https://doi.org/10.1200/jco.2014.58.4631 DOI: https://doi.org/10.1200/JCO.2014.58.4631
25. Wethmar K, Matern S, Eßeling E, Angenendt L, Pfeifer H, Brüggemann M, Stelmach P, Call S, Albring JC, Mikesch JH, Reicherts C, Groth C, Schliemann C, Berdel WE, Lenz G, Stelljes M. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. Bone Marrow Transplant. 2020;55(7):1410–20. https://doi.org/10.1038/s41409-020-0801-0 DOI: https://doi.org/10.1038/s41409-020-0801-0
26. Gang M, Othus M, Walter RB. Significance of measurable residual disease in patients undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Cells. 2025;14(4):290. https://doi.org/10.3390/cells14040290 DOI: https://doi.org/10.3390/cells14040290
27. Spyridonidis A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood. 2020;135(19):1639–49. https://doi.org/10.1182/blood.2019003566 DOI: https://doi.org/10.1182/blood.2019003566
28. Mo X, Lv M, Huang X. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post‐transplantation minimal residual disease (MRD) monitoring and MRD‐directed intervention. Br J Haematol. 2017;179(2):184–97. https://doi.org/10.1111/bjh.14778 DOI: https://doi.org/10.1111/bjh.14778
29. Pincez T, Santiago R, Bittencourt H, Louis I, Bilodeau M, Rouette A, Jouan L, Landry JR, Couture F, Richer J, Teira P, Duval M, Cellot S. Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children. Bone Marrow Transplant. 2021;56(12):2981–9. https://doi.org/10.1038/s41409-021-01408-5 DOI: https://doi.org/10.1038/s41409-021-01408-5
30. Tavares RDCB, Pelegrina PRD. Prevention and management of relapse of acute leukemia and myelodysplastic syndrome after allogeneic hematopoietic cell transplantation in pediatric patients. J Bone Marrow Transplant Cell Ther. 2021;2(4):131. https://doi.org/10.46765/2675-374X.2021v2n4p131 DOI: https://doi.org/10.46765/2675-374X.2021v2n4p131
31. Llaurador G, Nicoletti E, Prockop SE, Hsu S, Fuller K, Mauguen A, O’Reilly RJ, Boelens JJ, Boulad F. Donorhost lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: influence of pretransplantation variables and correlation with post-transplantation outcomes. Transplant Cell Ther. 2021;27(9):780.e1–e14. https://doi.org/10.1016/j.jtct.2021.05.020 DOI: https://doi.org/10.1016/j.jtct.2021.05.020
32. Horn B, Wahlstrom JT, Melton A, Liou A, Ouachee-Chardin M, Sunkersett G, Willert J, Hwang J, Expose- Spencer J, Cowan MC, Facchino J, Dvorak CC. Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia. Pediatr Blood Cancer. 2017;64(8):10.1002/pbc.26464. https://doi.org/10.1002/pbc.26464 DOI: https://doi.org/10.1002/pbc.26464
33. Delie A, Verlinden A, Beel K, Deeren D, Mazure D, Baron F, Breems D, De Becker A, Graux C, Lewalle P, Maertens J, Poire X, Schoemans H, Selleslag D, Van Obbergh F, Kerre T. Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. Acta Clin Belg. 2021;76(6):500–8. https://doi.org/10.1080/17843286.2020.1754635 DOI: https://doi.org/10.1080/17843286.2020.1754635
34. Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD. AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. Bone Marrow Transplant. 2016;51(9):1245–8. https://doi.org/10.1038/bmt.2016.90 DOI: https://doi.org/10.1038/bmt.2016.90
35. Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, Greco R, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Kuball J, Hazenberg MD, Ruggeri A; Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11(6):e448–58. https://doi.org/10.1016/s2352-3026(24)00098-x DOI: https://doi.org/10.1016/S2352-3026(24)00098-X
36. Jaiswal SR, Chakrabarti A, Chatterjee S, Bhargava S, Ray K, O’Donnell P, Chakrabarti S. Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transplant. 2016;22(3):499–504. https://doi.org/10.1016/j.bbmt.2015.11.010 DOI: https://doi.org/10.1016/j.bbmt.2015.11.010
37. Swaminathan VV, Uppuluri R, Patel S, Sivashankaran M, Ravichandran N, Ramanan KM, Ramakrishnan B, Vaidhyanathan L, Raj R. Safety and efficacy of fresh whole blood donor lymphocyte infusion in children. Bone Marrow Transplant. 2019;54(11):1892–7. https://doi.org/10.1038/s41409-019-0580-7 DOI: https://doi.org/10.1038/s41409-019-0580-7
38. Vago L, Toffalori C, Ciceri F, Fleischhauer K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 2012;39(6):707–15. https://doi.org/10.1053/j.seminoncol.2012.09.009 DOI: https://doi.org/10.1053/j.seminoncol.2012.09.009
39. Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, Halkes CJM, de Wreede LC. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation. Front Immunol. 2024;15:1335341. https://doi.org/10.3389/fimmu.2024.1335341 DOI: https://doi.org/10.3389/fimmu.2024.1335341
40. Geramita E, Hou JZ, Shlomchik WD, Ito S. Maintenance strategies for relapse prevention and treatment. Hematol Am Soc Hematol Educ Program. 2024;2024(1):635–43. https://doi.org/10.1182/hematology.2024000589 DOI: https://doi.org/10.1182/hematology.2024000589
41. Aygüneş U, Karagün BŞ, Şaşmaz I, Antmen AB. The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantations: A single-center experience. Clin Transplant. 2024;38(5):15366. https://doi.org/10.1111/ctr.15366 DOI: https://doi.org/10.1111/ctr.15366
42. Horton TM, Whitlock JA, Lu X, O’Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. Br J Haematol. 2019;186(2):274–85. https://doi.org/10.1111/bjh.15919 DOI: https://doi.org/10.1111/bjh.15919
43. Yanagi M, Mori M, Honda M, Mitani Y, Seki M, Fukuoka K, Oshima K, Arakawa Y, Koh K. Nelarabine containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma. Int J Hematol. 2024;119(3):327–33. https://doi.org/10.1007/s12185-023-03701-z DOI: https://doi.org/10.1007/s12185-023-03701-z
44. Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, Attarbaschi A, Brown PA, Gardner RA, Gaynon PS, Hutchinson R, Huynh VT, Jeha S, Marcus L, Messinger Y, Schultz KR, Cassar J, Locatelli F, Zwaan CM, Wood BL, Sposto R, Gore L. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022;69(11):29901. https://doi.org/10.1002/pbc.29901 DOI: https://doi.org/10.1002/pbc.29901
45. Basile G, Galtier J, Cazaubiel T, Forcade E, Klein E, Bidet A, Botella-Garcia C, Mediavilla C, Clement L, Dumas PY, Pigneux A, Leguay T. Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitor. EJHaem. 2025;6(1):1064. https://doi.org/10.1002/jha2.1064 DOI: https://doi.org/10.1002/jha2.1064
46. Aubert L, Petit A, Bertrand Y, Ray-Lunven AF, Angoso M, Pluchart C, Millot F, Saultier P, Cheikh N, Pellier I, Plantaz D, Sirvent A, Thouvenin-Doublet S, Valduga J, Plat G, Rialland F, Henry C, Esvan M, Gandemer V. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. Pediatr Blood Cancer. 2022;69(2):e29441. https://doi.org/10.1002/pbc.29441 DOI: https://doi.org/10.1002/pbc.29441
47. Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022;36(6):1516–24. https://doi.org/10.1038/s41375-022-01576-3 DOI: https://doi.org/10.1038/s41375-022-01576-3
48. Rubinstein JD, O’Brien MM. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Front Immunol. 2023;14:1237738. https://doi.org/10.3389/fimmu.2023.1237738 DOI: https://doi.org/10.3389/fimmu.2023.1237738
49. O’Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, Xu X, Yi JS, Harris AC, Brown PA, Borowitz MJ, Militano O, Kairalla J, Devidas M, Raetz EA, Gore L, Loh ML. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: children’s oncology group protocol AALL1621. J Clin Oncol. 2022;40(9):956–67. https://doi.org/10.1200/jco.21.01693 DOI: https://doi.org/10.1200/JCO.21.01693
50. Guo HP, Liu Y, Kang L, Liu C, Qin WW. Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis. Hematol Amst Neth. 2024;29(1):2422151. https://doi.org/10.1080/16078454.2024.2422151 DOI: https://doi.org/10.1080/16078454.2024.2422151
51. Bruzzese A, Martino EA, Labanca C, Caridà G, Mendicino F, Lucia E, Olivito V, Puccio N, Neri A, Morabito F, Vigna E, Gentile M. Therapeutic strategies for relapsed or refractory B‐cell acute lymphoblastic leukemia in adult patients: optimizing the use of monoclonal antibodies. Eur J Haematol. 2025;114(6):938–52.https://doi.org/10.1111/ejh.14405 DOI: https://doi.org/10.1111/ejh.14405
52. Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puyó P, Micalizzi C, Rossig C, Shukla N, Gilad G, Locatelli F, Baruchel A, Zwaan CM, Bezler NS, Rubio-San-Simón A, Taussig DC, Raetz EA, Mao ZJ, Wood BL, Alvarez Arias D, Krevvata M, Nnane I, Bandyopadhyay N, Lopez Solano L, Dennis RM, Carson R, Vora A. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144(21):2237–47. https://doi.org/10.1182/blood.2024024493 DOI: https://doi.org/10.1182/blood.2024024493
53. Vakrmanová B, Nováková M, Říha P, Žaliová M, Froňková E, Mejstříková E, Starý J, Hrušák O, Šrámková L. CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics. Pediatr Blood Cancer. 2022;69(9):e29779. https://doi.org/10.1002/pbc.29779 DOI: https://doi.org/10.1002/pbc.29779
54. Wilson A, Moussa A, Trinquand A, Malone A, Tewari S, Calvert R, Patrick K, Nicholson E, Smith K, Grandage V, Baird S, George L, Qureshi A, Borg A, Gibson B, Patel P, Bartram J, Samrin L, O’Connor D. Real-world use of venetoclax in the treatment of paediatric and teenage/young adult haematological malignancies. Br J Haematol. 2024;205(6):2355–62. https://doi.org/10.1111/bjh.19791 DOI: https://doi.org/10.1111/bjh.19791
55. Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440–53. https://doi.org/10.1158/2159-8290.cd-20-1465 DOI: https://doi.org/10.1158/2159-8290.CD-20-1465
56. Badawi MA, Gopalakrishnan S, Engelhardt B, Palenski TL, Kim SY, Karol SE, Rubnitz JE, Menon R, Salem AH. Proposed scheme for dosing venetoclax in pediatric patients with relapsed/refractory acute myeloid leukemia: analysis of developmental pharmacokinetics and exposure-response relationships. Blood. 2020;136(Suppl. 1):11–2. https://doi.org/10.1182/blood-2020-139593 DOI: https://doi.org/10.1182/blood-2020-139593
57. Varadarajan I, Pierce E, Scheuing L, Morris A, El Chaer F, Keng M. Post-hematopoietic cell transplantation relapsed acute lymphoblastic leukemia: current challenges and future directions. OncoTargets Ther. 2023;16:1–16. https://doi.org/10.2147/ott.s274551 DOI: https://doi.org/10.2147/OTT.S274551
58. Wang SS, Abbott RC, Gilsenan M, Duke T, Khaw SL. Chimeric antigen receptor T cell therapy in childhood leukaemia. Arch Dis Child. 2025;110(7):503–9. https://doi.org/10.1136/archdischild-2024-328263 DOI: https://doi.org/10.1136/archdischild-2024-328263
59. Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, Yanir AD, Buechner J, Elhasid R, Bielorai B, Rogosic S, Dourthe ME, Maschan M, Rossig C, Toren A, von Stackelberg A, Locatelli F, Bader P, Zimmermann M, Bourquin JP, Baruchel A. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022;36(6):1525–32. https://doi.org/10.1038/s41375-022-01546-9 DOI: https://doi.org/10.1038/s41375-022-01546-9
60. Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40(9):945–55. https://doi.org/10.1200/jco.20.03585 DOI: https://doi.org/10.1200/JCO.20.03585
61. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O’Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16(1):45–63. https://doi.org/10.1038/s41571-018-0075-2 DOI: https://doi.org/10.1038/s41571-018-0075-2
62. Ortí G, Peczynski C, Boreland W, O’Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z. Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study. Leukemia. 2025; 39(2): 431–7. https://doi.org/10.1038/s41375-024-02467-5 DOI: https://doi.org/10.1038/s41375-024-02467-5
63. de Melo Rodrigues AL, Bonfim C, Seber A, Colturato VAR, Zecchin VG, Nichele S, Daudt LE, Fernandes JF, Vieira AK, Darrigo Junior LG, Gomes AA, Arcuri L, Lenzi L, Picharski GL, Ribeiro RC, de Figueiredo BC. Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil: a multicentric retrospective study. Cell Transplant. 2020;29:963689720949175. https://doi.org/10.1177/0963689720949175 DOI: https://doi.org/10.1177/0963689720949175
64. Egan G, Tasian SK. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica. 2023;108(9):2275–88. https://doi.org/10.3324/haematol.2022.281106 DOI: https://doi.org/10.3324/haematol.2022.281106
65. Rasche M, Zimmermann M, Steidel E, Alonzo T, Aplenc R, Bourquin JP, Boztug H, Cooper T, Gamis AS, Gerbing RB, Janotova I, Klusmann JH, Lehrnbecher T, Mühlegger N, Neuhoff NV, Niktoreh N, Sramkova L, Stary J, Waack K, Walter C, Creutzig U, Dworzak M, Kaspers G, Kolb EA, Reinhardt D. Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG. Cancers. 2021;13(10):2336. https://doi.org/10.3390/cancers13102336 DOI: https://doi.org/10.3390/cancers13102336
66. Rasche M, Steidel E, Zimmermann M, Bourquin JP, Boztug H, Janotova I, Kolb EA, Lehrnbecher T, von Neuhoff N, Niktoreh N, Mühlegger N, Sramkova L, Stary J, Walter C, Creutzig U, Dworzak M, Reinhardt D. Second relapse of pediatric patients with acute myeloid leukemia: a report on current treatment strategies and outcome of the AML-BFM study group. Cancers. 2021;13(4):789. https://doi.org/10.3390/cancers13040789 DOI: https://doi.org/10.3390/cancers13040789
67. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39(25):2768–78. https://doi.org/10.1200/jco.20.03736 DOI: https://doi.org/10.1200/JCO.20.03736
68. Masetti R, Baccelli F, Leardini D, Gottardi F, Vendemini F, Di Gangi A, Becilli M, Lodi M, Tumino M, Vinci L, Erlacher M, Strahm B, Niemeyer CM, Locatelli F. Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis. Blood Adv. 2023; 7(16):4366–70. https://doi.org/10.1182/bloodadvances.2023010113 DOI: https://doi.org/10.1182/bloodadvances.2023010113
69. Pommert L, Tarlock K. The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/ IDH/BCL2 inhibitors, and other therapies. Hematol Am Soc Hematol Educ Program. 2022; 2022(1): 603–10. https://doi.org/10.1182/hematology.2022000358 DOI: https://doi.org/10.1182/hematology.2022000358
70. Karol SE, Gueguen G. Pediatric acute myeloid leukemia - novel approaches. Curr Opin Hematol. 2024;31(2):47–52. https://doi.org/10.1097/MOH.0000000000000795 DOI: https://doi.org/10.1097/MOH.0000000000000795
71. Lamble AJ, Tasian SK. Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Adv. 2019;3(22):3750–8. https://doi.org/10.1182/bloodadvances.2019000357 DOI: https://doi.org/10.1182/bloodadvances.2019000357
72. Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, Silvestris DA, Sinibaldi M, Di Cecca S, Pitisci A, Velardi E, Merli P, Algeri M, Lodi M, Paganelli V, Serafini M, Riminucci M, Locatelli F, Quintarelli C. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;1 5(1):163. https://doi.org/10.1186/s13045-022-01376-3 DOI: https://doi.org/10.1186/s13045-022-01376-3
73. Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, Foster M, Schappe T, McClain E, Pence PP, Desai S, Kersting-Schadek S, Wong P, Russler-Germain DA, Fisk B, Lie WR, Eisele J, Hyde S, Bhatt ST, Griffith OL, Griffith M, Petti AA, Cashen AF, Fehniger TA. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022; 139(11):1670–83. https://doi.org/10.1182/blood.2021013972 DOI: https://doi.org/10.1182/blood.2021013972
74. Knight TE, Edwards H, Meshinchi S, Taub JW, Ge Y. “FLipping” the story: FLT3-mutated acute myeloid leukemia and the evolving role of FLT3 inhibitors. Cancers. 2022;14(14):3398. https://doi.org/10.3390/cancers14143398 DOI: https://doi.org/10.3390/cancers14143398
75. Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, Fisher B, Hirsch B, Kahwash S, Getz K, Levine J, Brodersen LE, Loken MR, Raimondi S, Tarlock K, Wood A, Sung L, Kolb EA, Gamis A, Meshinchi S, Aplenc R. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the Children’s Oncology Group Protocol AAML1031. J Clin Oncol. 2022;40(18):2023–35. https://doi.org/10.1200/jco.21.01612 DOI: https://doi.org/10.1200/JCO.21.01612
76. Sweeney C, Vyas P. The graft-versus-leukemia effect in AML. Front Oncol. 2019;9:1217. https://doi. org/10.3389/fonc.2019.01217 DOI: https://doi.org/10.3389/fonc.2019.01217
77. Shah NA. Donor lymphocyte infusion in acute myeloid leukemia. Best Pract Res Clin Haematol. 2023;36(3):101484. https://doi.org/10.1016/j.beha.2023.101484 DOI: https://doi.org/10.1016/j.beha.2023.101484
78. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020;126(10):2183–92. https://doi.org/10.1002/cncr.32769 DOI: https://doi.org/10.1002/cncr.32769
79. Graff Z, Wachter F, Eapen M, Lehmann L, Cooper T. Navigating treatment options and communication in relapsed pediatric AML. Am Soc Clin Oncol Educ Book. 2024;44(3):e438690. https://doi.org/10.1200/edbk_438690 DOI: https://doi.org/10.1200/EDBK_438690
80. Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, Kreyenberg H, Bager R, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Ullrich E, Bakhtiar S, Rettinger E, Jarisch A, Soerensen J, Klingebiel TE, Bader P. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplant. 2017;52(2):201–8. https://doi.org/10.1038/bmt.2016.224 DOI: https://doi.org/10.1038/bmt.2016.224
81. Sakaguchi H, Miyamura T, Tomizawa D, Taga T, Ishida H, Okamoto Y, Koh K, Yokosuka T, Yoshida N, Sato M, Noguchi M, Okada K, Hori T, Takeuchi M, Kosaka Y, Inoue M, Hashii Y, Atsuta Y. Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. Bone Marrow Transplant. 2021;56(8):1859–65. https://doi.org/10.1038/s41409-021-01250-9 DOI: https://doi.org/10.1038/s41409-021-01250-9
82. Shem-Tov N, Saraceni F, Danylesko I, Shouval R, Yerushalmi R, Nagler A, Shimoni A. Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant. 2017;23(7):1087–94. https://doi.org/10.1016/j.bbmt.2017.03.023 DOI: https://doi.org/10.1016/j.bbmt.2017.03.023
83. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica. 2013;98(2):179–84. https://doi.org/10.3324/haematol.2012.073189 DOI: https://doi.org/10.3324/haematol.2012.073189
84. Frietsch JJ, Hunstig F, Wittke C, Junghanss C, Franiel T, Scholl S, Hochhaus A, Hilgendorf I. Extra medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant. 2021;56(1):101–9. https://doi.org/10.1038/s41409-020-0984-4 DOI: https://doi.org/10.1038/s41409-020-0984-4
85. Huang Q, Reddi D, Chu P, Snyder DS, Weisenburger DD. Clinical and pathologic analysis of extramedullary tumors after hematopoietic stem cell transplantation. Hum Pathol. 2014;45(12):2404–10. https://doi.org/10.1016/j.humpath.2014.07.022 DOI: https://doi.org/10.1016/j.humpath.2014.07.022
86. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015;50(8):1057–62. https://doi.org/10.1038/bmt.2015.82 DOI: https://doi.org/10.1038/bmt.2015.82
87. Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, Sedlacek P, Guengoer T, Lang P, Bader P, Sufliarska S, Balduzzi A, Strahm B, von Luettichau I, Hoell JI, Borkhardt A, Klingebiel T, Schrappe M, von Stackelberg A, Glogova E, Poetschger U, Meisel R, Peters C. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL‐SCT 2003/2007 trial. Br J Haematol. 2018;180(1):82–9. https://doi.org/10.1111/bjh.14965 DOI: https://doi.org/10.1111/bjh.14965
88. Pastore F, Levine RL. Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica. 2016;101(3):269–78. https://doi.org/10.3324/haematol.2015.140822 DOI: https://doi.org/10.3324/haematol.2015.140822
89. Hazar V, Karasu GT, Uygun V, Özbek N, Karakükçü M, Öztürk G, Daloğlu H, Kılıç SÇ, Aksu T, Ünal E, Koçak Ü, Yeşilipek A, Akçay A, Gürsel O, Küpesiz A, Okur FV, İleri T, Kansoy S, Bayram İ, Karagün BŞ, Gökçe M, Kaya Z, Ok Bozkaya İ, Patıroğlu T, Aksoylar S. Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group. Leuk Lymphoma. 2020;61(6):1465–74. https://doi.org/10.1080/10428194.2020.1716220 DOI: https://doi.org/10.1080/10428194.2020.1716220
90. Hazar V, Tezcan Karasu G, Öztürk G, Küpesiz A, Aksoylar S, Özbek N, Uygun V, İleri T, Okur FV, Koçak Ü, Kılıç SÇ, Akçay A, Güler E, Kansoy S, Karakükcü M, Bayram İ, Aksu T, Yeşilipek A, Karagün BŞ, Yılmaz Ş, Ertem M, Uçkan D, Fışgın T, Gürsel O, Yaman Y, Bozkurt C, Gökçe M; Turkish Pediatric Bone Marrow Transplantation Study Group. Prognostic factors for survival in children who relapsed after allogeneic hematopoietic stem cell transplantation for acute leukemia. Pediatr Transplant. 2021;25(5):e13942. https://doi.org/10.1111/petr.13942 DOI: https://doi.org/10.1111/petr.13942
91. Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transplant. 2018;24(8):1629–42. https://doi.org/10.1016/j.bbmt.2018.03.002 DOI: https://doi.org/10.1016/j.bbmt.2018.03.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rita de Cássia Barbosa Tavares, Polliany Roberta Dorini Pelegrina, Carla Nolasco Monteiro Breviglieri, Ana Luiza de Mello Rodrigues, Gustavo Zamperlini, Adriana Martins de Sousa, Patricia Regina Cavalcanti Barbosa Horn, Luiz Guilherme Darrigo Jr, Liane Daudt
This work is licensed under a Creative Commons Attribution 4.0 International License.
